Biomarker: D001-IgE D pteronyssinus

Overview

D001-IgE measures serum immunoglobulin E antibodies directed against the house dust mite Dermatophagoides pteronyssinus. Allergen-specific IgE can bind to immune cells and contribute to immediate hypersensitivity reactions after exposure to the relevant allergen. A detectable or elevated result indicates sensitization to D. pteronyssinus, but does not by itself confirm symptomatic allergy or predict reaction severity. The test is clinically useful as part of an evaluation for house dust mite-associated allergic rhinitis, asthma, or atopic dermatitis, alongside exposure history and symptoms.

Clinical Use Cases

Support evaluation of suspected house dust mite allergy.
Identify sensitization to D. pteronyssinus in patients with allergic rhinitis, asthma, or atopic dermatitis.
Help identify relevant allergens when skin-prick testing is unsuitable, including in patients with extensive dermatitis, dermatographism, or inability to stop antihistamines.
Support selection of patients for house dust mite allergen immunotherapy when the test result is consistent with clinical history.
Assess sensitization in research studies involving house dust mite allergy and allergen-specific immune responses.
Guide further evaluation with component-resolved testing or allergen provocation when the clinical relevance of sensitization is uncertain.

Specimen Types

Venous blood, usually processed as serum.
Serum or plasma may be accepted by some validated assay systems, according to the performing laboratory’s requirements.

Measurement Methods

Automated allergen-specific immunoassay, commonly a fluorescence enzyme immunoassay.
Enzyme-linked immunosorbent assay or other enzyme-labeled immunometric assays.
Multiplex allergen microarray or component-resolved diagnostics for individual mite allergens such as Der p 1, Der p 2, and Der p 23.
Results are commonly reported in allergen-specific IgE units such as kUA/L or IU/mL, with assay-specific classes or interpretive categories.
Skin-prick testing is an alternative in-vivo method for detecting sensitization, but it is not a measurement of serum D001-IgE.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergy blood test.
Patients should report all prescription medicines, over-the-counter medicines, and supplements.
Antihistamines can interfere with skin-prick testing, but generally do not prevent measurement of serum-specific IgE. Medication instructions should come from the healthcare provider.
Patients should not stop prescribed medicines unless instructed by a healthcare professional.
Total IgE concentration, age, atopic dermatitis, immune status, assay characteristics, and the selected reporting threshold may affect interpretation.
A positive result indicates sensitization and should be interpreted with symptoms, timing of exposure, and environmental history.
The numerical concentration does not reliably predict the severity of future reactions.
Cross-reactivity with related allergens may contribute to a positive result.
A negative result reduces the likelihood of detectable systemic sensitization but does not completely exclude clinically relevant allergy, particularly when symptoms suggest local allergic disease or when testing is performed with an incomplete allergen extract.
Serum-specific IgE cannot consistently distinguish clinically relevant allergy from asymptomatic sensitization. Nasal or other allergen provocation testing may be required in selected cases.